(Q36089354)

12 August 2017

1 reference

title

The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials (English)

1 reference

12 August 2017

0 references

R C Mohs

1

1 reference

PubMed ID

15810901

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Genes, Brain and Behavior

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

129-133

1 reference

12 August 2017

3

1 reference

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Documentation and evaluation of cognitive impairment in elderly primary care patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Functional decline in Alzheimer's disease: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

The impact of behavioral impairment of functional ability in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Longitudinal study of death and institutionalization in patients with primary degenerative dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Alzheimer's disease care: costs and potential savings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Current concepts in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1601-183X.2004.00112.X

10.1111/J.1601-183X.2004.00112.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15810901